Director and 10% Owner Sells $489K in Atara Biotherapeutics Stock
ATRA is trading near its 52-week low of $4.252 (7.7% above the low) on elevated volume (4.0× avg).
Summary
James Huang, a Director and 10% owner of Atara Biotherapeutics, sold common stock valued at $489,019 at an average price of $6.07, a significant disposition relative to the company's market capitalization.
Key Events · Ownership and Investor Activity · ATRA
-
Insider Sale
James Huang, a Director and 10% owner, disposed of 80,554 shares of Atara Biotherapeutics common stock.
-
Significant Value
The sale amounted to $489,019, a substantial transaction for the company.
-
Transaction Price
Shares were sold at a weighted average price of $6.07 on January 12, 2026, compared to the current stock price of $4.58.
Analysis · ATRA · Life Sciences
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
At the time of this filing, ATRA was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.2M. The 52-week trading range was $4.25 to $19.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.